Showing 1451-1460 of 1692 results for "".
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0606Dementia-pdf/31301/Dementia in Parkinson’s Disease: Diagnostic Challenges and Emerging TreatmentsDavid S. Geldmacher, MD, highlights the complexities in diagnosing dementia associated with Parkinson’s disease (PDD) in his Practical Neurology column. Despite Parkinson’s disease (PD) primarily being recognized as a move
- Protecting Stroke Patients from Seizureshttps://practicalneurology.com/diseases-diagnoses/stroke/pn0407-post-stroke-pdf/31194/Post-Stroke Seizures: Epidemiology, Classification, and ManagementAs the global population ages, the incidence of post-stroke seizures is expected to rise, highlighting their clinical significance in neurology. Stroke markedly increases the risk of seizures, with a 23- to 35-fold higher incidence co
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN1105dementia-pdf/31374/Managing challenging behaviors in dementia patients remains a significant hurdle for both clinicians and caregivers. In his insightful commentary for Practical Neurology, Dr. David S. Geldmacher highlights the complexities associated with treating behavioral and psychiatric symptoms of dementia (BPS
- Seeing the Other Side of Parkinson's Diseasehttps://practicalneurology.com/diseases-diagnoses/movement-disorders/PN0405Parkinsons-pdf/31469/Parkinson’s disease (PD), first described by James Parkinson in 1817, has long been a challenging condition for physicians due to limited treatment options. Historically, management was primarily palliative, focusing on maintaining patient comfort as motor control and autonomic functions progressive
- Making the Switch: When and How to Step-Up MS Therapyhttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN1108MS-pdf/30974/Advancements and Considerations in Multiple Sclerosis TherapeuticsOver the past quarter-century, Multiple Sclerosis (MS) treatment has evolved rapidly, marked by the FDA approval of six disease-modifying therapies (DMTs) with several more in development. This acceleration contrasts with the decade-l
- Giving Your Practice a Check-uphttps://practicalneurology.com/columns/practice-management/giving-your-practice-a-check-up/31182/Optimizing Neurology Practice Management for Enhanced Efficiency and RevenueIn the competitive landscape of neurology medicine, optimizing practice management is crucial for both patient care and financial sustainability. Drawing parallels with the disciplined regimen of professional athletes, neuro
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN1206DementiaInsights-pdf/31235/CATIE-AD Study Reassesses Atypical Antipsychotics in Alzheimer’s DiseaseA recent analysis of the CATIE-AD (Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer’s Disease) study challenges the efficacy and safety of atypical antipsychotic medications in managing behavioral symptom
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31277/Optimizing Antihypertensive Therapy for Stroke Prevention: Insights for NeurologistsAntihypertensive therapy stands as the cornerstone of stroke prevention, significantly reducing stroke recurrence more effectively than many other medical interventions, including antiplatelet and cholesterol-lowerin
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0306dementia-pdf/31333/Unintended Cognitive Effects of Anticholinergic Medications in Neurology PracticeAnticholinergic medications, widely prescribed for various conditions, pose significant cognitive risks, particularly in elderly patients and those with Alzheimer’s disease (AD). A community-based French study highlight
- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31419/Idiopathic Hypersomnia: A Distinct Clinical Entity Beyond NarcolepsyIn a case highlighted by Robert Fayle, MD, a 31-year-old woman with a longstanding history of excessive daytime sleepiness (EDS) since age 14 presents a compelling example of idiopathic central nervous system hypersomnia. Unlike nar